This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ؍ 60
Precore mutation of hepatitis B virus in HBE antigen positive chronic hepatitis B in association with response to interferon-alpha
✍ Scribed by Fujimoto, K.; Kato, M.; Kaneko, A.; Yamamoto, K.; Kurosawa, K.; Masuzawa, M.
- Book ID
- 122075968
- Publisher
- Elsevier Science
- Year
- 1998
- Tongue
- English
- Weight
- 166 KB
- Volume
- 114
- Category
- Article
- ISSN
- 0016-5085
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Precore defective HBV mutants may gradually prevail because of immune selection and explain spontaneous seroconversion from HBeAg to anti-HBe in HBV carriers. We have analyzed whether the presence of precore HBV mutants is a determinant of responsiveness to interferon-a therapy. Fifteen carriers (ni
We previously reported two mutually exclusive mutations in the precore region of hepatitis B virus: MI (T-1856, proline-serine substitution at codon 15) and M 2 (A-1896, stop codon at codon 28). This study was conducted to determine if the presence of precore mutants affect spontaneous or interferon
The objective of this study was to evaluate the role of hepatitis B virus (HBV) precore mutations in patients with anti-me-positive chronic hepatitis B with or without previous known HBe antigen (HBeAg) viremic phase, and to assess the potential implication of precore mutants in HBeAg-negative react